Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CG210** is a patented topical botanical lotion developed for treating androgenetic alopecia (AGA) in both men and women, featuring a unique blend of onion bulb extract (Allium cepa), lemon fruit extract (Citrus medica Limonum), cocoa seed extract (Theobroma cacao), and guarana seed extract (Paullinia cupana). It operates via a triple mechanism of action distinct from existing therapies: it increases Bcl-2 anti-apoptotic protein levels (up to 89.9%) to prolong the anagen phase and prevent premature follicle cell apoptosis, attenuates scalp micro-inflammation by enhancing Langerhans cells (73.9% increase in CD1A+ cells) and cellular proliferation (41.7% increase in Ki-67+), and boosts scalp collagen by 79.9% after 4 months to support healthier hair implantation. Clinical trials demonstrate reduced hair shedding to normal levels within 44 days, 11% increase in anagen hairs after 3 months, and 37.7% greater hair diameter increase versus placebo when combined with finasteride over 12 months, with high patient satisfaction (96% clinical improvement), excellent safety (no side effects reported), and hypoallergenic, non-oily formulation eligible for EMA centralized herbal medicine registration.[1][2][3][5][7][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CG210.